Bisindolylmaleimide XI hydrochloride (Ro 32-0432) is a potent, selective and orally activePKCinhibitor withIC₅₀s of 9 nM, 28 nM, 31 nM, 37 nM, and 108 nM forPKCα,PKCβI,PKCβII,PKCγ, andPKCε, respectively^[1][2].

Bisindolylmaleimide XI hydrochloride (Ro 32-0432) inhibits IL-2 secretion, IL-2 receptor expression in, and proliferation of, peripheral human T-cells stimulated with phorbol ester together with phytohemagglutin or anti-CD3, but does not inhibit IL-2 induced proliferation in cells already stimulated to express IL-2 receptors. Proliferation of the influenza peptide antigen HA 307-319-specific human T-cell clone (HA27) after exposure to antigen-pulsed autologous presenting cells is also inhibited by Bisindolylmaleimide XI hydrochloride^[2].
PKC inhibition with Bisindolylmaleimide XI hydrochloride (Ro 32-0432; 1 μM) decreases the proportion of apoptotic cells (-21%) in retinal progenitor cells (RPCs)^[3].

Oral administration of Bisindolylmaleimide XI hydrochloride inhibits subsequent phorbol ester-induced edema in ratss. Induction of more physiologically T-cell driven responses such as host vs. graft responses and the secondary paw swelling in adjuvant-induced arthritis are also inhibited by Bisindolylmaleimide XI hydrochloride^[2].

489.01

Solid

C₂₈H₂₉ClN₄O₂

145333-02-4

Room temperature in continental US; may vary elsewhere.

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)